A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Wang D, Wang J, Hu G, Wang W, et al. Blood 2021;137:2890-2901.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang D, Wang J, Hu G, Wang W, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood 2021;137:2890-2901.
PMID: 33512480